Unicycive Therapeutics, Inc.
UNCY
$0.64
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | 0.00 |
| SG&A Expenses | 3.97M | 3.21M | 2.53M | 2.39M | 2.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.26M | 6.25M | 7.40M | 9.21M | 6.31M |
| Operating Income | -9.26M | -6.25M | -7.40M | -9.21M | -6.31M |
| Income Before Tax | -21.53M | -4.10M | 9.86M | -20.96M | -7.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.53M | -4.10M | 9.86M | -20.96M | -7.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.53M | -4.10M | 9.86M | -20.96M | -7.80M |
| EBIT | -9.26M | -6.25M | -7.40M | -9.21M | -6.31M |
| EBITDA | -9.25M | -6.25M | -7.40M | -9.20M | -6.31M |
| EPS Basic | -0.20 | -0.05 | 0.08 | -0.44 | -0.22 |
| Normalized Basic EPS | -0.13 | -0.03 | 0.16 | -0.38 | -0.14 |
| EPS Diluted | -0.20 | -0.05 | -0.15 | -0.44 | -0.22 |
| Normalized Diluted EPS | -0.13 | -0.03 | 0.07 | -0.38 | -0.14 |
| Average Basic Shares Outstanding | 105.72M | 88.94M | 37.91M | 34.88M | 34.86M |
| Average Diluted Shares Outstanding | 105.72M | 88.94M | 94.05M | 34.88M | 34.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | 0.00% | 11.11% | -- | -- |